HYALURONAN INDUCED TARGETING

What this means for you

This application is over — abandoned 30 Jul 1997. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number

74593429

Mark type

Word mark

Filed

01 Nov 1994

Abandoned

30 Jul 1997

Attorney of record

IVOR M. HUGHES

Goods and services

• Class 005 — Pharmaceuticals: pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable, and intravenous treatment of the following - cancer, increasing activity of macrophages; reduction of swelling in the brain of person suffering brain trauma; herpes, canker sore, shingles; renal failure, cardiac insufficiency, hypertension, edema; infection, acne, monoucleosis; transplants; inflammation, elminiation of tumor breakdown material (toxins and debris), decreasing side effects, relief of pain; detoxification; bronchodilation; vascular ischemia; HIV (AIDS); diabetes; post-menopause; prevention of topical infection; reduction of swelling; hypertension, cardiac insufficiency; prostaglandin synthesis inhibition; enhancement of oxygenation of tissue by perfusion fluid bathing of the tissue (for transplantation purposes); sub-retinal neovascularization and as an adjunct to the treatment of cancer to prevent metastasis; arthitis or pannus; cancer tumours; inhibiting angiogenesis; controlling angiogenesis; regressing angiogenesis; basal cell carcinoma; actinic keratones; liver spots; squamous cell tumours; metastatic cancer of the breast to the skin; primary and metastatic melanoma of the skin; malignancies and/or tumor of the skin; genital warts (condyloma acuminata); cervical cancer; Human Papilloma Virus (HPV); psoriasis, corns on the feet; and hair loss on the heads of pregnant women; topical treatment of pain in the skin and or exposed tissue; clearing of atherosclerosis; prevention of arterial restenosis after balloon angioplasty; macrophage infilitration
• Class 042 — Scientific and technological services: acquisition, development and licensing of intellectual property technology regarding pharmaceutical preparations comprising hyaluronan, adapted for the topical, injectable and intravenous treatment of medical conditions and disease in humans

Owner

• HYAL PHARMACEUTICAL CORPORATION, Toronto, Ontario, CA

Prosecution history

• 25 Aug 1997 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
• 29 Jan 1997 — INQUIRY AS TO SUSPENSION MAILED
• 06 Jun 1996 — UNRESPONSIVE/DUPLICATE PAPER RECEIVED
• 04 Jun 1996 — INQUIRY AS TO SUSPENSION MAILED
• 06 Jan 1996 — LETTER OF SUSPENSION MAILED
• 16 Oct 1995 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 18 Apr 1995 — NON-FINAL ACTION MAILED
• 17 Mar 1995 — ASSIGNED TO EXAMINER